Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Deals

Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics

Fineline Cube Nov 22, 2022

Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...

Company Drug

Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China

Fineline Cube Nov 22, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...

Company Drug

Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors

Fineline Cube Nov 22, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...

Company Drug

Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy

Fineline Cube Nov 22, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...

Company Drug

Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP

Fineline Cube Nov 22, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...

Company Deals

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Fineline Cube Nov 22, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...

Company Drug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

Fineline Cube Nov 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...

Company Drug

Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic

Fineline Cube Nov 22, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...

Company Drug

Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong

Fineline Cube Nov 21, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...

Company Drug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Fineline Cube Nov 21, 2022

China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...

Company Deals Medical Device

ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development

Fineline Cube Nov 21, 2022

Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of...

Company Drug

Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera

Fineline Cube Nov 21, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...

Policy / Regulatory

China’s CDE, HNMPA, and Bo’ao Lecheng Release Real-world Drug Research Measures

Fineline Cube Nov 21, 2022

The Center for Drug Evaluation (CDE), Hainan Medical Products Administration (HNMPA), and Bo’Ao Lecheng Medical...

Company Medical Device

Hotgen Biotech Receives FDA EUA for COVID-19 Antigen Home Test

Fineline Cube Nov 21, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving Emergency Use Authorization (EUA) from...

Company Deals

Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis

Fineline Cube Nov 21, 2022

Holland-based information and software solutions provider Wolters Kluwer has announced a partnership with China’s National...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Company Deals

Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem

Fineline Cube Nov 21, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...

Company Drug

Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC

Fineline Cube Nov 21, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...

Company Drug

Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV

Fineline Cube Nov 21, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

Fineline Cube Nov 21, 2022

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...

Posts pagination

1 … 553 554 555 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.